Item 1.01 Entry Into a Material Definitive Agreement.



On July 26, 2022, Haemonetics Corporation (the "Company") entered into an
amended and restated credit agreement by and among the Company, as borrower, the
lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as
administrative agent (the "Revised Credit Agreement"). The Revised Credit
Agreement amends and restates the Company's pre-existing credit agreement, dated
as of June 15, 2018, by and among the Company, as borrower, the lenders from
time to time party thereto and JPMorgan Chase Bank, N.A., as administrative
agent (as amended by that certain Amendment No. 1 dated as of March 1, 2021, the
"2018 Credit Agreement") to, among other things, refinance the credit facilities
under the 2018 Credit Agreement and extend the maturity date of such credit
facilities by two years to June 2025.

The Revised Credit Agreement provides for a $280 million senior unsecured term
loan, the proceeds of which have been used to retire the balance of the term
loan under the 2018 Credit Agreement, and a $420 million senior unsecured
revolving credit facility, which constitutes a $70 million increase from the
revolving credit facility under the 2018 Credit Agreement. Loans under the
Revised Credit Agreement will initially bear interest at an annual rate equal to
the Adjusted Term SOFR Rate (as defined in the Revised Credit Agreement), which
is subject to a floor of 0%, plus an applicable rate ranging from 1.125% to
1.750% based on the Company's Consolidated Net Leverage Ratio (as defined in the
Revised Credit Agreement) at the applicable measurement date. Adjusted Term SOFR
Rate loans are also subject to a credit spread adjustment of 0.10% per annum.
The revolving credit facility carries an unused fee that ranges from 0.125% to
0.250% annually based on the Company's Consolidated Net Leverage Ratio at the
applicable measurement date. The revolving credit facility and term loan
facility also permit U.S. dollar borrowings at a base rate specified in the
Revised Credit Agreement and the revolving credit facility permits borrowings
denominated in other currencies which, if incurred, would bear interest at the
respective rates set forth in the Revised Credit Agreement. The Revised Credit
Agreement matures on June 15, 2025. The principal amount of the term loan under
the Revised Credit Agreement amortizes quarterly through the maturity date at a
rate of 2.5% for the first year and 5% thereafter, with the unpaid balance due
at maturity.

The Revised Credit Agreement contains financial covenants that require that the
Company maintain (i) a maximum Consolidated Net Leverage Ratio of 3.50x or, on
up to two occasions during the term of the facility, 4.00x for the four
consecutive fiscal quarters ended immediately following the consummation of a
Qualifying Material Acquisition (meaning one or more Permitted Acquisition(s)
(as defined in the Revised Credit Agreement) for which the aggregate
consideration paid over a 12-month period exceeds $100 million) and (ii) a
minimum Consolidated Interest Coverage Ratio (as defined in the Revised Credit
Agreement) of 4.00x. The Consolidated Net Leverage Ratio is calculated based on
earnings before interest, taxes, depreciation and amortization, as adjusted
pursuant to the Revised Credit Agreement ("Consolidated EBITDA"). The Company is
permitted to exclude from Consolidated EBITDA, among other things, (i) unusual
or non-recurring charges or expenses not to exceed the greater of 17.5% of
Consolidated EBITDA or $35 million and (ii) transaction costs related to the
closing of Permitted Acquisitions or other permitted Investments (as defined in
the Revised Credit Agreement) not to exceed $15 million per acquisition or
Investment. In addition, the Company is generally permitted to deduct up to $100
million in certain cash and cash equivalents maintained in the United States by
the Company and its subsidiaries from the Consolidated Total Debt (as defined in
the Revised Credit Agreement) component of the Consolidated Net Leverage Ratio.
The Revised Credit Agreement also includes customary affirmative and negative
covenants that include exceptions that permit the Company to, among other
things, incur up to $250 million in Indebtedness (as defined in the Revised
Credit Agreement) related to the acquisition, construction or improvement of any
fixed or capital assets, including certain capital lease obligations, and places
no fixed dollar limits on the Company's ability to enter into operating leases
or undertake acquisitions or other Investments, subject to the Company's
compliance with its financial covenants and so long as no Event of Default (as
defined in the Revised Credit Agreement) has occurred and is continuing or would
result from such actions by the Company.

A copy of the Revised Credit Agreement is attached hereto as Exhibit 10.1 and is
incorporated herein by reference. The foregoing description of the Revised
Credit Agreement is qualified in its entirety by reference to the full text of
the Revised Credit Agreement.



--------------------------------------------------------------------------------

Item 1.02 Termination of a Material Definitive Agreement.

The information set forth under Item 1.01 is hereby incorporated by reference into this Item 1.02.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

(a)

The information set forth under Item 1.01 is hereby incorporated by reference into this Item 2.03.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit Number            Description
  10.1                    Amended and Restated Credit Agreement, dated as

of July 26, 2022, by and among


                          the Company, the lenders from time to time party

thereto and JPMorgan Chase

Bank, N.A., as administrative agent
104                       Cover Page Interactive Data File (embedded within

the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses